Orladeyo® (berotralstat) is an oral, once‐daily, highly selective inhibitor of plasma kallikrein recently approved for prevention of angioedema attacks in adults and adolescents with HAE.29 The gene discussed is KLK4; the disease is hereditary angioedema.